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Abstract
Increased expression of the transient receptor potential vanilloid 1 (TRPV1) channels, following nerve injury, may facilitate
the entry of QX-314 into nociceptive neurons in order to achieve effective and selective pain relief. In this study we
hypothesized that the level of QX-314/capsaicin (QX-CAP) - induced blockade of nocifensive behavior could be used as an
indirect in-vivo measurement of functional expression of TRPV1 channels. We used the QX-CAP combination to monitor the
functional expression of TRPV1 in regenerated neurons after inferior alveolar nerve (IAN) transection in rats. We evaluated
the effect of this combination on pain threshold at different time points after IAN transection by analyzing the escape
thresholds to mechanical stimulation of lateral mental skin. At 2 weeks after IAN transection, there was no QX-CAP mediated
block of mechanical hyperalgesia, implying that there was no functional expression of TRPV1 channels. These results were
confirmed immunohistochemically by staining of regenerated trigeminal ganglion (TG) neurons. This suggests that TRPV1
channel expression is an essential necessity for the QX-CAP mediated blockade. Furthermore, we show that 3 and 4 weeks
after IAN transection, application of QX-CAP produced a gradual increase in escape threshold, which paralleled the
increased levels of TRPV1 channels that were detected in regenerated TG neurons. Immunohistochemical analysis also
revealed that non-myelinated neurons regenerated slowly compared to myelinated neurons following IAN transection. We
also show that TRPV1 expression shifted towards myelinated neurons. Our findings suggest that nerve injury modulates the
TRPV1 expression pattern in regenerated neurons and that the effectiveness of QX-CAP induced blockade depends on the
availability of functional TRPV1 receptors in regenerated neurons. The results of this study also suggest that the QX-CAP
based approach can be used as a new behavioral tool to detect dynamic changes in TRPV1 expression, in various
pathological conditions.
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Introduction
Neuropathic pain (NP), which may arise as a result of injury,
inflammation, or disease of the peripheral or central nervous
systems, is characterized by spontaneous pain (i.e. ongoing,
paroxysmal) and evoked sensitization in the form of hyperalgesia
or allodynia. The TRPV1 channel, which is classically associated
with transduction of painful stimuli such as hot temperature, low
pH and application of vanilloid substances [1,2,3,4] has been
shown to change its expression profile under neuro-pathological
conditions. Such changes have been implicated in neuropathic
pain, by underlying changes in neuronal excitability [5,6,7,8,9,10].
Several reports have described changes in TRPV1 expression
levels in neuropathic pain models. Decrease of TRPV1 levels in
injured and increased expression of TRPV1 in uninjured or spared
neurons, was reported to occur after nerve ligation/transection
[5,6,7,8,9,10], however, the dynamics of functional TRPV1
expression during regeneration of transected nerves in this respect
is still elusive. This information is highly important when exploring
therapeutically relevant avenues in which TRPV1 may play an
essential role. In naı¨ve animals, TRPV1 is exclusively expressed in
peripheral C- and Ad- fibers [1]. Contrary to its role as a
transducer in pain fibers, TRPV1 has been shown to serve also as
a carrier for selective blockers of excitability. Blocking pain fibers
specifically can be achieved by exploiting the selective TRPV1
expression in these fibers and the ability to use TRPV1 as a carrier
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of neuronal excitability blockers such as the non-permeable
sodium channel blocker N-(2,6-dimethylphenylcarbamoylmethyl)
triethylammonium bromide (QX-314). QX-314 is a permanently
positively charged sodium channel blocker, which is unable to
readily cross the cell membrane in a passive manner [11,12,13,14].
However, when opening the TRPV1 channel by capsaicin, QX-
314 can enter and thereby block nociceptive sodium channels
from the inside of the cell, producing a long-lasting, pain-specific
local anesthesia, devoid motor or tactile deficits [15,16,17,18].
Based on the fact that TRPV1 plays a major role in this strategy,
we explored whether the combination of QX-314 together with
capsaicin (QX-CAP) could be used, not only to understand the
dynamic functional expression of TRPV1 during regeneration of
injured nerves, but also to block nerve injury mediated hyperal-
gesia. We further examined where (i.e. cell types) TRPV1 is
expressed following IAN transection and nerve regeneration. This
information is essential for better understanding mechanisms of
pain, and thereby allowing development of novel strategies to
manage pain. In this study we used the combination of QX-314
and capsaicin that was developed for selective blocking of pain
[15,16,17] to understand the functional expression of TRPV1 in
conjunction with profiling TRPV1 expression by immunohisto-
chemistry. We show that starting 3 weeks after nerve transection,
the QX-CAP combination reduces the hypersensitivity in the area
of nerve regeneration and that this is dependent upon the amount
of nerve regeneration in the injured area and the level of TRPV1
expression in these nerves. We further show a shift in the
expression of TRPV1 from non-myelinated regenerated nerves to
myelinated regenerated nerves and compare this data between
those animals which underwent hyperalgesia and those which did
not, as result of induced nerve transection (as a model for nerve
injury induced neuropathic pain) hinting to the fact that other
fibers besides nociceptive fibers participate in inducing pain
sensation. Finally we propose using the behavioral testing as a tool
to qualitatively relay relative TRPV1 expression levels after nerve
injury is initiated.
For the first time we can give an accurate account not only of
changes in TRPV1 expression (both in time and cell type) but
cross correlate this to behavioral testing and blockade of painful
sensation. This novel approach for targeted painful stimuli in a
neuropathic pain model can serve as a platform to be developed
into clinically relevant strategies for pain management.
Methods
The experiments were carried out in accordance with the
guidelines of National Institute of Health Guide for the Care and
Use of Laboratory (NIH Publication no. 80–23) revised 1996 and
the International Association for the Study of Pain in conscious
Animals, and were approved by the intramural Animal Care and
Veterinary Science Committee of Niigata University [19]. Surgery
was performed under sodium pentobarbital anesthesia, and all
efforts were made to minimize suffering.
A total of 120 male rats (Sprague-Dawley), weighing 150–200
grams at the start of the experiment, were used. The rats were
exposed to a light dark cycle of 12 hours. Food and water were
available ad libitum.
IAN Transection and Sham Operation
Rats were anesthetized with sodium pentobarbital (50 mg/kg,
administered intraperitoneally (IP)), which was proceeded with left
IAN transection. In this procedure, the rats were placed on a
warm mat (to control for normal bodily temperature) and a small
incision was made in the facial skin over the masseter muscle. The
muscle was dissected to expose the surface of the alveolar bone.
The bone covering IAN was removed using a dental drill. The
exposed IAN was lifted, transected, and then placed back in the
mandibular canal without any discernible gap between the cut
ends [20,21].
Rats with a similar facial skin dissection but without IAN
exposure and transection were categorized as the sham-operated
group (QX-CAP administration: n=15, CAP administration:
n=15) in all experiments performed. After surgery, all animals
received penicillin G potassium (20,000 units) intramuscularly, to
prevent infection.
Behavioral Testing and Division of Rats into Groups
In daily sessions, rats were trained to stay in a plastic cage and
keep their snout protruding through a hole in the cage wall during
mechanical stimulation of the mental skin, using von Frey
filaments (Touch-Test Sensory Evaluators; North Coast Medical,
Inc., CA, USA). Touching and rubbing the rat’s mental skin
without painful stimuli, by the shaft of von Frey filaments every
day for 5–7 days (when the rats kept their snout protruded),
allowed training the rats to keep their snout protruding through
the hole for a long period of time. The force used, which brought
upon escape behavior was determined and defined as the escape
threshold (Fig 1). After successful training, the escape threshold
was determined for the mental skin area, before and after IAN
transection. The rats were free to escape following von Frey
stimulus. Such escape behavior was defined as nocifensive. To
determine the escape threshold, von Frey mechanical stimuli were
applied to the mental skin in ascending and descending series of
trials. The von Frey stimulus was applied 5 times in each series of
trials. Escape threshold intensity was determined when the rats
moved their heads away from the hole in at least one of the 5
stimuli. The average threshold intensity was calculated from the
values after 2 ascending and 1 descending series of trials.
Mechanical escape thresholds were measured at pre and 3 days,
2, 3, and 4 weeks post IAN transection.
The IAN-transected rats (IANx) were divided into neuropathic
pain (NP) and non-neuropathic pain (non-NP) groups according to
the following criteria: the rats that showed a mechanical escape
threshold of #8 gram (g) after IAN transection were considered to
have developed NP [20,21,22]. Each group was further divided
into 3 subgroups, according to the time (in weeks) elapsed after
IAN transaction and the escape threshold before QX-CAP
administration. QX-CAP administration was performed at 2, 3
and 4 weeks following IAN transection. The rats that showed an
escape threshold of #8 g at 2 weeks after IAN transection were
defined as the 2-week NP group (n=15). The rats that showed an
escape threshold of #8 g at 2 weeks after IAN transection, which
remained constant also at 3 weeks, were named the 3-week NP
group (n=15). The rats that showed an escape threshold of #8 g
at 2 weeks after IAN transection, which remained constant also at
3 and 4 weeks, were defined as the 4-week NP group (n=15). In
the non-NP group (escape threshold following IAN .8 g), the rats
were similarly divided into the 2-week non-NP (n=15), 3-week
non-NP (n=15), and 4-week non-NP (n=15) groups respectively,
in order to evaluate behavioral responses in an extended period of
between 2–4 weeks following transection similar to the NP groups.
Drugs and Chemicals
N-(2,6-dimethylphenylcarbamoylmethyl) triethylammonium
bromide (QX-314) (Sigma-Aldrich, St. Louis, USA) was used as
a 2% solution in normal saline (0.9% NaCl in distilled water).
Capsaicin solution (Wako Pure Chemical Industries, Ltd., Osaka,
Japan) was prepared with Tween 20 (10%), ethanol (10%), and
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normal saline (80%). QX-314 was freshly prepared on the day of
the experiment. Capsaicin solution was prepared every 15 days
and kept in the refrigerator (4uC). Before commencement of
individual experiments, capsaicin solution was equilibrated at
room temperature for 30 min.
Injection of Drugs and Behavioral Testing
During each experimental session, preinjection mechanical
escape thresholds of the mental skin area were measured ipsilateral
to IAN transection. QX-314 (2%, 50 ml) with capsaicin (1 mg/ml,
30 ml) solution was subcutaneously injected into the mental skin
area on the side ipsilateral to IAN transection, using a Hamilton
microsyringe. In the sham-operated group, the solution of QX-314
with capsaicin or capsaicin was injected into the left mental skin
area. Following injection, the escape threshold from the ipsilateral
side was measured at 15 and 30 min, 1, 2, 3, 4, 5, 6, 7, and 24 h
after injection. In the sham-operated group, the escape threshold
from the left mental skin area was measured.
Immunohistochemistry
Five rats were chosen randomly from each group and used for
the immunohistochemical experiments. Fluoro-Gold (FG) (2%,
10 ml) was subcutaneously injected into the mental skin area under
sodium pentobarbital (50 mg/kg, administered intraperitioneally)
anesthesia, 2 days before perfusion and used for retrograde
labeling of neurons in order to give an estimate of the extent of
regeneration following the IAN procedure. Then the rats were
deeply anesthetized with sodium pentobarbital and perfused with
200 ml of normal saline followed by 500 ml of 4% paraformal-
dehyde. The trigeminal ganglion (TG) was removed and post-fixed
in 4% paraformaldehyde, for 2 days and the tissue was then
transferred to a solution of 20% sucrose in phosphate-buffered
saline (PBS) for several days for cryoprotection. Sections (16 mm in
thickness) were cut using a cryostat, and every fifth section was
mounted on MAS-coated glass slides (Matsunami Glass Ind., Ltd.,
Osaka, Japan). After washing with PBS, the sections were
incubated at room temperature with 3% normal goat serum
(NGS) in 0.01 M PBS with 0.3% Triton X-100, for 1.5 hours.
They were then coincubated overnight at 4uC with a combination
of rabbit anti-TRPV1 antibody (1:200; Alomone Labs Ltd., Israel),
which was diluted with 3% NGS in 0.01 M PBS with 0.3% Triton
X-100, and mouse monoclonal anti-neurofilament 200 (NF200)
antibody (1:1000; Sigma-Aldrich), which was diluted with 3%
NGS in 0.01 M PBS with 0.3% Triton X-100. The sections were
washed 3 times with PBS and then incubated with goat anti-rabbit
IgG (Alexa Fluor 488, 1:1000; Invitrogen, USA) and goat anti-
mouse IgG (Alexa Fluor 568, 1:1000; Invitrogen) for 2 h at room
temperature. After washing with PBS, the slides were coverslipped
with Vectashield mounting medium (Vector Laboratories, Inc.,
USA). The stained slides were viewed and imaged using a camera
attached to a Biozero BZ-8000 fluorescent microscope (Keyence
Corp., Japan). The area viewed at 100x (7006850 mm) at the root
of the third branch of TG was used for counting labeled cells. For
each rat, three sections (one with the largest number of labeled
cells and the next two sections) were selected for counting.
The cell area was measured using ImageJ software (NIH Image,
USA) for cells expressing TRPV1, NF200, and FG. A cell area
.1000 mm2 was considered large, while that ,1000 mm2 was
considered medium and ,400 mm2 was considered small [20].
Statistical Analysis
For the analysis of the last significant time point of the
behavioral effect of QX-CAP, one way analysis of variance
(ANOVA) followed by Dunnett’s test were used. For comparison
of the magnitude of the effect, the area under curve (AUC) was
calculated and compared using a t-test. In addition, the
comparison between different groups was tested statistically using
two-way ANOVA. Immunohistochemical data were analyzed
using one-way ANOVA followed by the Student–Newman–Keuls
test. To compare TRPV1 expressing regenerated myelinated and
non-myelinated neurons between the same groups paired t-test
was used. To compare changes in distribution of the area of cells
expressing TRPV1 channels, 3 slices from each rat for each group
were compared. Since the distribution of cell areas did not follow
Gaussian distribution (analyzed by Shapiro-Wilk and Kolmogorov
Smirnov test), the cumulative probability of the areas of the
examined cells was calculated. Data were then fit by a Boltzmann
relationship: y = (A1– A2/(1+ exp [(x-x(0))/dx] =A2), and the x(0)
(which is the cell area at which of 50% of examined cells express
TRPV1 channels), was calculated for each group and compared
using one-way ANOVA with post-hoc Bonferroni. p value ,0.05
was considered as statistically significant. Data are expressed as
mean 6 standard deviation.
Results
Application of capsaicin, by virtue of its activation of TRPV1
channels, facilitates the entry of the permanently charged
membrane impermeant sodium channel blocker, QX-314, selec-
tively into nociceptive neurons, and thereby produces pain-
selective analgesia [15,16,17]. Here we examined whether this
platform could be also used to attenuate neuropathic pain resulting
from nerve injury. We wanted to explore the dynamic effective
range of the QX-CAP combination in sham-operated as well as
those animals which underwent inferior alveolar nerve transection
(IANx) and developed neuropathic pain (NP). To this end, we
measured the mechanical escape threshold of the mental region of
rats before and after subcutaneous application of QX-CAP into
this area, at different time points after IANx. In sham operated
animals, subcutaneous application of QX-CAP lead to significant
and robust increase of the escape threshold, which lasted for 3.5
hours (post-hoc Dunnett’s test) and then decreased to near basal
levels as before sham operation (Fig 1A), though only CAP
application in sham rats showed that the escape threshold
reduction lasted over 6 hours (Fig 1B). This was not the case
with the NP groups tested before and after QX-CAP application.
In the 2-week NP group (the rats that showed a mechanical escape
threshold of #8 g 2 weeks after IANx) there was a transient
increase in threshold which is attributed to deinneravation
followed by a steady state decrease in the threshold prior to
application. Following QX-CAP application, there was no
significant increase in response to mechanical stimuli after the
Figure 1. The effect of QX-CAP application on the escape threshold of NP and non-NP group at different time points after IAN
transection. The changes in escape threshold following subcutaneous application of QX-CAP in sham-operated group (A); Only CAP injected sham-
operated group (B); 2-weeks NP group (C); 2-weeks non-NP group (D); 3-weeks NP group (E); 3-weeks non-NP groups (F); 4-weeks NP group (G); 4-
weeks non-NP group (H). The measurement were performed before the transection, 3 days after transection, 2, 3, and 4 weeks after transection/sham
operation (depending on groups) and at various time points after injection of QX-CAP or CAP (n = 15 for each group, ANOVA followed by Dunnett’s
test, *p,0.05). QX: QX-314; CAP: Capsaicin; Preop.: Preoperation; Preinj.: Preinjection; Pretrans.: Pretransection.
doi:10.1371/journal.pone.0044023.g001
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initial decrease in threshold (p.0.05, one-way ANOVA followed
by Dunnett’s test) (Fig 1C). In the 3-and 4-week NP groups, the
profile of change in mechanical threshold before QX-CAP
application was similar to that of the 2 week group (Fig 1E, G).
However, application of capsaicin and QX-314 at 3 and 4 weeks
transiently reversed the IANx-mediated decrease in escape
threshold (Fig 1E, G). In the 3-week NP group, the QX-CAP
mediated increase in the escape threshold lasted for 3 hours and
was significantly higher than that of the 2-week NP group (AUC3-
weeks NP = 2619.66811; AUC2 weeks NP = 1495.561074, p = 0.017,
t-test, p,0.001, two way ANOVA) (Fig 1C, E) but significantly
lower than the effect shown for the sham operated group
(AUCSham=931761069, p,0.001, t-test; p,0.001, two way
ANOVA) (Fig 1A, E). In the 4-week NP group, the observed
effect lasted also for 3 hours (post-hoc Dunnett’s test) and was
significantly higher than the 3-week NP group (p,0.001, AUC
analysis; p,0.001, two way ANOVA) (Fig 1E, G) but still
significantly lower than that of the sham operated group (p,0.001
AUC analysis, p,0.001, two way ANOVA). To further explore
the reasons for these results, we looked into the extent of
regeneration, as evidenced by retrograde fluoro-gold FG+ labeling.
The lack of response in the 2 week group could not be explained
by lack of the fibers innervating the mental skin, since we observed
significant regeneration (Fig 2 and Fig 3A). We found that the
extent of regeneration increased as time went by from the 2 week
group and up to the 4 week group, albeit a smaller extent than the
sham operated group.
Since the effect of QX-CAP strongly depends on activation of
TRPV1 channels, we further explored whether the lack of
response in the 2 week group could be due to the diminished
TRPV1 expression in this NP group. We found that the relative
amount of TRPV1 expressing cells among FG+ trigeminal
ganglion neurons in the 2-week NP group was, however,
significantly smaller than in the sham operated group (the ratio
of TRPV1++FG+ to all FG + positive cells in the 2 week NP group
was 24.564.4% and the ratio of TRPV1++FG+ to all FG + positive
cells in the sham operated group was 63.563.9%) (Fig 2 and
Fig 3C, E). Moreover, the ratio of TRPV1++FG+ to all FG+
positive cells in the 3-week NP group was higher than the 2-week
NP group (4163.8%) (Fig 2 and Fig 3E). In the 4-week NP group,
the ratio was even higher than in the 3-week NP group
(52.865.2%) (Fig 2 and Fig 3E), but still did not reach the level
of the sham operated group (63.563.9%). We found a clear
positive correlation between the extent of the QX-CAP effect in
the different groups and increased TRPV1 expression in the
regenerated neurons (Fig 2 and Fig 3C, E). Since there was no
effect for QX-CAP at 2 weeks after IANx, we assumed that QX-
314 alone cannot explain the results shown in the other groups. It
is also apparent that at 2 weeks there were enough sensory fibers
and sufficient excitability to allow for the decreased painful
threshold. Thus, we conclude that the effect of QX-CAP is the
result of increased TRPV1 expression in the regenerating neurons
and that the effect is targeted blockade of sodium channels via
TRPV1 channels as demonstrated in other pain related models
[15,16,17,18]. This approach can be used as an effective pain
treatment taking into account the time constrains of TRPV1
expression along the timeline of regeneration after nerve injury.
This result also allows for indirect measurement of TRPV1
expression as evident from changes in pain related behavior (i.e.
threshold).
In addition to realizing the effect of TRPV1 expression on the
behavior, we explored its dynamic expression profile between
different neuronal cell types. To this end we used myelinated
neuron marker NF-200 (NF) to examine the effect of IANx on the
expression of TRPV1 channels among myelinated
(TRPV1++FG++NF+) and non-myelinated (TRPV1++FG++NF-)
regenerated neurons. As expected from previous results, the
number of TRPV1++FG++NF- cells, which can account for the
pain sensing C-fibers was very low in the 2-week NP group
(5.963.5) compared to the sham (80.4613.5) (Fig 2 and Fig 3I).
Surprisingly, although the total number of TRPV1++FG+ cells in
the 3-week NP group was significantly higher than in the 2-week
NP group (Fig 2 and Fig 3C), the number of TRPV1++FG++NF-
neurons wasn’t statistically different from the 2-week NP group
(5.963.5 vs. 16.165.5, respectively, p.0.05, one-way ANOVA
followed by the Student–Newman–Keuls test) (Fig 2 and Fig 3I).
However we found that most of the TRPV1 expression was
attributed to myelinated neurons (Fig 2 and Fig 3I). Indeed, while
in the sham-operated group the number of TRPV1++FG++NF-
cells (63.8% of the total TRPV1++FG+ cells (Fig 2 and Fig 3C, I)
was significantly higher than that of TRPV1++FG++NF+ cells
(36.2% of the total TRPV1++FG+ cells (Fig 2 and Fig 3C, G), in
the NP groups, the number of TRPV1++FG++NF- cells was
significantly lower than that of TRPV1++FG++NF+ cells (67%–
76% across the different groups vs. 23%–32% across the different
groups, respectively). The number of TRPV1++FG++NF- gradu-
ally increases (16.165.5 vs. 2865.9, for 3-weeks NP and 4-weeks
NP, respectively, p,0.05, one-way ANOVA followed by the
Student–Newman–Keuls test) (Fig 2 and Fig 3I). Even the 4 week
NP group had significantly lower TRPV1 expression than in the
sham operated group (2865.9 vs. 80.4613.5 in 4-week NP and
sham operated groups, respectively, p,0.001, one-way ANOVA
followed by the Student–Newman–Keuls test) for non myelinated
neurons (Fig 2 and Fig 3I).
The number of the TRPV1++FG++NF+ cells also increased
after NP injury to levels higher than the sham-operated group
(Fig 2 and Fig 3G) (57.865.9 vs. 45.665.1, 4 week group and
sham operated group respectively, p,0.01, one-way ANOVA
followed by the Student–Newman–Keuls test) but the amount of
myelinated regenerated neurons (NF++FG+) without TRPV1 did
not change with time (Fig 2 and Fig 3K).
Collectively, these data show that the pattern of expression of
TRPV1 channels changes after nerve injury, such that TRPV1
channel expression shifts to become more prominent in myelin-
ated neurons, the importance of which will be discussed down
below.
As stated in the above method section, the animals were divided
into NP and non-NP groups according to which animals
developed nocifensive behavior (i.e. change in threshold occurring
after IAN). It was important to explore why certain animals did
not show a decrease in the mechanical threshold and whether this
observation has any link to TRPV1 expression profiles following
IANx.
Similarly to the NP groups, the number of TRPV1++FG+ cells
gradually increased with time after the transection (Fig 2 and
Fig 3C). However the level of TRPV1-expressing regenerated cells
Figure 2. Photomicrographs of immunohistochemistry of TG cells labeled for TRPV1, NF200 and FG in sham-operated group and in
2-; 3-and 4-week NP groups and in 2-; 3- and 4 weeks non-NP groups. Expanded view of TG in the sham-operated group (D1–D4). Arrow
points on an example of TRPV1++FG++NF- cell. Arrowhead points on an example of TRPV1++FG++NF+ cell. Note that TRPV1-positive cells increased
with time after transection. Scale bar: 50 mm.
doi:10.1371/journal.pone.0044023.g002
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was significantly higher in non-NP groups than in NP groups
(p,0.001 for all NP vs. non NP groups, one-way ANOVA
followed by the Student–Newman–Keuls test). In the 2 week non-
NP group about 40% (43.662.2%) (Fig 2 and Fig 3F) of the
regenerated cells expressed TRPV1, whereas in the 2 week NP
group, only about 25% of the regenerated trigeminal neurons
expressed TRPV1 (24.564.4%). The number of TRPV1++FG+
neurons in the 3-week non-NP group was higher than that of the
2-week non-NP group (84.466.2 vs. 5665.2, respectively,
p,0.001, one-way ANOVA followed by the Student–Newman–
Keuls test) but significantly lower than in the 4-week non-NP
group (112.2610.4) (p,0.001, one-way ANOVA followed by the
Student–Newman–Keuls test), and reached near control levels (in
sham operated group, 126618.2) 4 weeks after injury (p.0.05,
one-way ANOVA followed by the Student–Newman–Keuls test;
Fig 2 and Fig 3D). Moreover the absolute number of regenerating
neurons increased with time, reaching near sham levels at 4 weeks
(Fig 2 and Fig 3D). However the amount of regenerating neurons
at any time point was significantly higher when compared to levels
seen for the NP groups, which might hint to a larger and more
robust behavioral effect when applying QX-CAP in conjunction to
TRPV1 levels per regenerating nerves (compare Fig 3F to Fig 3E).
Based on these results and those of Fig 1, we speculated that this
expression profile would lead to more profound effects of QX-
CAP application in terms of increasing threshold levels. Indeed
this was the case. Application of QX-CAP to the mental skin of
non-NP animals produced a significant increase of escape
threshold in all non-NP groups (Fig 1D, F, H), including the 2
week group, for which there was no effect in the NP animals
(Fig 1C vs. Fig 1D). It is important to mention that the behavioral
profile in general between all groups was the same. The initial
increase in threshold preceding the IAN transection was also
evident in the non-NP groups, indicating that the procedure was
complete and the difference in effects seen between NP and non-
NP groups could not be the result of a difference in the IAN
procedure. However the question of difference in threshold
between the groups prior to QX-CAP application still remains
elusive. The duration of QX-CAP mediated effect was similar in
all non-NP groups and also when compared to the NP groups,
namely a transient 3 hour effect which then returned back to
baseline (p,0.05, one-way ANOVA followed by Dunnett’s test).
The magnitude of the blockade in the 2-week non-NP group was
not significantly different from that seen in the 3-week non-NP
group, according to AUC (AUC2-weeks non-NP = 571361327 vs.
AUC3-weeks non-NP = 6590.161696) (p.0.05, t-test) (Fig 1D, F).
However, analysis performed by two-way ANOVA with post-hoc
Bonferroni comparing specific time points, did show a statistical
significant difference between the groups (30 min, 1, 1.5, 2 and 3
hour post injection). However, the effect seen in the 4-week non-
NP group was significantly higher than in the 2 and 3 week non-
NP groups (AUC4-weeks non-NP = 8361.561637; p,0.001, t-test;
p,0.001 two way ANOVA) (Fig 1D, F, H).The effect of QX-CAP
mediated blockade in the 4-week non-NP group was similar to the
effect on sham operated animals according to AUC analysis of
data (AUCSham= 931761069; p.0.05, t-test) but different when
using specific time point in two-way ANOVA analysis (Fig 1A, E).
The effect in the sham operated group was higher than that of the
4-week non-NP group at 30 min, 2 and 4 hour post injection. In
conclusion we see that the level of TRPV1 expression correlates to
magnitude of QX-CAP application across all non-NP groups.
We examined whether the pattern of distribution of TRPV1
channels is altered in non-NP nerve injury model and how this
compares to the NP groups. In general the pattern and change in
profile is similar. The non-NP groups exhibit increasing levels of
TRPV1 with time in myelinated regenerated neurons, surpassing
the level as shown in the sham group (Fig 2 and Fig 3H). Thus, at
4-weeks, the number of TRPV1++FG++NF+ cells (6766.5) was
significantly higher than in the sham operated group (45.665.1,
p,0.001, one-way ANOVA followed by the Student–Newman–
Keuls test) (Fig 2 and Fig 3J). The level of TRPV1 in non
myelinated neurons also increased with time but did not reach
sham levels (Fig 2 and Fig 3J). The number of TRPV1++FG++NF-
neurons at 4 weeks (45.264.6) was approximately half of the sham
operated group (80.4613.5) (Fig 2 and Fig 3J) (p,0.001, one-way
ANOVA followed by the Student–Newman–Keuls test). Similar to
NP groups, the proportion of the TRPV1++FG++NF+ cells was
significantly higher than that of TRPV1++FG++NF- cells (56%–
61% across the different groups (Fig 3D, H) vs. 38%–42% across
the different groups (Fig 3D, J, respectively).
Just as observed for the NP groups, here too, the number of
myelinated regenerated neurons without TRPV1 is high (compa-
rable to sham) and does not change with time (Fig 2 and Fig 3L).
These data indicate that the sensitivity or absence of sensitivity
which different groups (NP and non NP groups) show to painful
stimuli and development of neuropathic pain behavior, are not
necessarily linked to the biogenesis like process which ultimately
shapes the TRPV1 expression profile following IANx.
Since myelinated neurons were the major cell type to express
TRPV1, we explored the distribution of expression of TRPV1 as a
function of cell area (Fig 4). This would represent cell size and give
a more accurate indication of sub cell type. In all experimental
groups, most of the TRPV1++FG++NF+ cells were found to be
medium sized with averaged cell body areas of less than 1000 mm2
(Fig 4). However, the peak cell area distribution shifted to the right
following both NP (Fig 4B,D,F,H) and non-NP (Fig 4C,E,G, I)
IANx. These data suggest that nerve injury with or without altered
pain sensation changes the expression profile of TRPV1 channels,
not only to myelinated neurons but of a larger diameter (table1).
Discussion
In the current study, we measured, for the first time, the
functional dynamic expression of TRPV1 during the regeneration
process of transected IAN nerve in rats. Using the facilitated entry
Figure 3. IAN transection both in NP and non-NP groups changes the expression profile of TRPV1 to myelinated neurons of a larger
diameter. The total number of TG cells labeled for the fluoro-gold (FG+) (A: NP group, B: Non-NP group); TG cells that labeled for TRPV1 and FG
(TRPV1++FG+) in 2-; 3-and 4-week NP groups and in sham-operated group (C: NP group, D: Non-NP group). The ratio of TRPV1++FG+ to all FG+
positive cells (E: NP group, F: Non-NP group). n = 5 for each group, (ANOVA followed by the Student–Newman–Keuls test, *p,0.05). The number of
cells positive for TRPV1, FG and NF200 (TRPV1++FG++NF+) (G: NP group, H: Non-NP group); positive for TRPV1 and FG but not for NF200
(TRPV1++FG++NF-) (I: NP group, J: Non-NP group); positive for NF200 and FG (NF++FG+) (K: NP group, L: Non-NP group) in 2-; 3-and 4-week NP groups
and in sham-operated group revealed by immunohistochemistry. ANOVA followed by the Student–Newman–Keuls test. # indicates non-significant
difference. TRPV1++FG++NF- and TRPV1++FG++NF+ positive cells between the same groups are compared by paired t-test and the statistical
significances are shown in the figure (G and H). 1*24* indicate significant difference. 1: Sham TRPV1++FG++NF+ Vs TRPV1++FG++NF-, 2: 2-wk non-NP
TRPV1++FG++NF+ Vs TRPV1++FG++NF-, 3: 3-wk non-NP TRPV1++FG++NF+ Vs TRPV1++FG++NF-, 4: 4-wk non-NP TRPV1++FG++NF+ Vs TRPV1++FG++NF-.
p,0.05. n = 5 for each group.
doi:10.1371/journal.pone.0044023.g003
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of QX-314 through the TRPV1 channel activated by capsaicin,
we demonstrated that increasing amounts of TRPV1 expression
would allow for functional and selective blockade of painful
sensation following neuropathic based nerve injury (i.e. IAN). For
the first time, we could interpret the amount of TRPV1 expression
as an indication of successful anesthetic effect for QX-CAP and
vise versa. We are now able in this model to predict the
effectiveness of such a strategy at different time points following
nerve injury. We can now also use the behavioral tests as a bio
assay to predict relative TRPV1 expression levels.
Peripheral nerve transection followed by close apposition of the
cut ends leads to axon regeneration and subsequent re-innerva-
tions of the target tissue. Depending on the regeneration distance,
this process can take several weeks to months [23,24,25,26] and
involves various molecular and biophysical changes in sensory
neurons [27,28,29,30,31,32,33,34,35]. For example, nerve injury
is known to induce alteration in receptors, ion channels,
neuropeptides, signal transduction molecules, and growth related
proteins, as well as to increase the spontaneous activity and
receptive field of sensory neurons
[22,36,37,38,39,40,41,42,43,44,45,46,47,48]. These changes
could be attributed to the injury itself and/or the altered
environment encountered by regenerating axons at the injury site
and/or the target tissue, and lead to a neuropathic condition
characterized by allodynia or hyperalgesia [22,28,39,49]. The
effectiveness of QX-CAP injection may differ under these
abnormal conditions. In our study, we evaluated the effectiveness
of this combination in the sham-operated group at 2 weeks after
operation, which can be considered as the control condition, and
in various IAN-transected groups. In the IAN-transected groups,
we evaluated the effectiveness under NP (indicated by a decrease
in mechanical escape thresholds) and non-NP conditions (where
the mechanical escape threshold did not decrease). We also
evaluated the effectiveness of QX-CAP at various time points after
transection as the underlying environment may change with time
and such a study has not yet been performed. Evaluating the effect
of QX-CAP injection in various conditions allowed us to
comprehend the functional expression of TRPV1 in those
conditions and to evaluate the outcome of such manipulations.
In agreement with this view, QX-CAP injection showed
variable local anesthetic effects under different conditions. In the
sham-operated group, QX-CAP injection caused a significant
increase in the mechanical escape threshold for 3.5 h (Fig 1A).
The escape threshold reduction lasted over 6 hours when only
CAP was injected the sham-operated group. This result implies
that capsaicin-induced sensitization does not evoke in the capsaicin
concentration we used.
The escape threshold increased to more than 2 times the
preinjection level and in many cases, the mental skin was
insensitive to even the 60 g von Frey stimulus. Under non-NP
conditions at 4 weeks after IAN transection, the threshold was
found to be similar to that of the sham-operated group (Fig 1H).
These findings indicate that QX-CAP injection was highly
effective in these 2 groups. Under NP conditions, at 3 and 4
weeks after transection, a significant increase was observed in the
escape thresholds, indicating that QX-CAP produced an analgesic
effect in these groups, similar to the non-NP groups. We observed
that the effectiveness of QX-CAP injection depends on time
elapsed from transection and are positively correlated to increasing
expression levels of TRPV1. These observations are true for both
NP and non-NP groups. These results are in line with previous
studies performed on naive animals, whereby QX-CAP injection
was shown to produce an effective, nociceptor-specific local
anesthesia effect? [15,16,17]. QX-CAP injection into rat hind
paws resulted in a long-lasting increase in mechanical and thermal
nociceptive thresholds [16]. In a recent study, the co-application of
these drugs was observed to be effective in blocking pain signals in
the rat trigeminal system [17]. These studies showed that QX-314
entered through the activated TRPV1 channel.
In the current study we also evaluated the type of regenerated
neurons in which TRPV1 is expressed after nerve transection. As
mentioned above, we used NF200 as a marker for myelinated
neurons (including Ab and Ad) and also injected FG (a retrograde
tracer) into the mental skin area to identify the regenerated
neurons. We found that the regenerated neurons expressing
TRPV1 gradually increased over time after IAN transection
(Fig 3C, E and 3D, F). However, in rats that developed NP, the
number of regenerated neurons expressing TRPV1 was smaller
compared to those with non-NP at the same time points. In the 4-
week non-NP group, the number of regenerated neurons
expressing TRPV1 was similar to that in the sham-operated
group. Comparison of these immunohistochemical findings with
behavioral data suggested that the variable anesthetic effect of
QX-CAP injection appears to be due to the availability of TRPV1
receptors on regenerated neurons. In rats with NP at 2 weeks after
transection, the number of regenerated neurons expressing
TRPV1 was smaller compared to sham and the corresponding
non-NP group of 2 weeks, and the corresponding behavioral study
showed that QX-CAP injection was not effective. We hypothesize
that entry of QX-314 was limited due to reduced TRPV1
expression and therefore not sufficient to make the combination
effective in the behavioral readout test. In the 3-and 4-week NP
groups, TRPV1 was shown to be expressed in higher numbers in
myelinated (medium-sized) neurons and the analgesic effect that
Figure 4. The pattern of distribution of TRPV1 was altered in non-NP groups. The distribution area of TRPV1++FG++NF+ positive cells for all
experimental groups. A cell area .1000 mm2 was considered large, while that ,1000 mm2 was considered medium. Note that most of the cells were
in the medium range, and the peak distribution shifted to the right in the transected groups. n = 5 for each group.
doi:10.1371/journal.pone.0044023.g004
Table 1. The distribution analysis of cell area of TRPV1++FG++NF+ in different groups.
Sigmoidal fit:
Sham 2-wkNP 3-wk NP 4-wk NP 2-wk non-NP 3-wk non-NP 4-wk non-NP
x(0) (Mean6SD) 644.7613 82264.6 788.266.6 796.765.5 742.463.8 731.464.1 721.665.3
d(X) (Mean6SD) 101.6611.7 97.964 96.966 95.964.9 90.263.4 90.663.4 88.164.7
x(0): Sham vs. 2 weeks NP, p,0.001; Sham vs. 3 weeks NP, p,0.01; Sham vs. 4 weeks NP, p,0.001; Sham vs. 2 weeks non NP, p,0.01; Sham vs. 3 weeks non NP, p,0.05;
Sham vs. 4 weeks non NP, p,0.05. There was no significant difference in d(x). One-way ANOVA with post-hoc Bonfferoni, n = 5 for all groups.
doi:10.1371/journal.pone.0044023.t001
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we observed in the 3-and 4-week NP groups might have been
mediated by entry of QX-314 via TRPV1 channels in these
neurons, as well as through non-myelinated neurons with TRPV1.
The smaller effect of QX-CAP injection in the non-NP group at 2
and 3 weeks after transection is also probably due to the reduced
availability of TRPV1 in regenerated neurons. An interesting
question arises as to why certain animals develop decreased
threshold (the NP groups) and other do not (the non-NP groups)
although they both underwent the same procedure and to the
same extent? The results show that TRPV1 levels are generally
higher in the non-NP groups even at 2 weeks post IANx. Many
studies have associated painful sensation to TRPV1 expression as
this channel is considered to be the transducer of painful stimuli.
Therefore one would expect that higher levels of TRPV1 would
convey higher sensitivity to painful stimuli. Could this difference in
profile also indicate whether or not an animal will develop
neuropathy based painful stimuli? Could it be related also to the
extent of regeneration between the groups which is also higher in
the non-NP groups? These points need further investigation.
Insight into this subject has great relevance when crossing over to
the clinic and will be of great importance in developing new
strategies which distinguish between different groups but also offer
the right protocol to diminish pain for those which unfortunately
fall into the NP groups.
The immunohistochemical study revealed that C-fibers (non
myelinated TRPV1 expressing neurons) were slow to regenerate
after transection, and this regeneration was even slower under NP
conditions compared to non-NP conditions. This data is in
conjunction with previous reports showing that the C-fibers of
injured nerves take longer to regenerate than myelinated A-fibers
[23,25,50,51]. Saito and colleagues showed that regenerated TG
neurons with small diameter were significantly reduced at 14 and
60 days after IAN transection [21], though it has been reported
that TRPV1 function is upregulated in IB4-positive sensory
neurons (small neurons) [52]. They demonstrated that IAN-
transected rats showed a profound reduction to thermal stimuli.
Thermal sensory information is predominantly conveyed by C-
fibers [53,54]. Therefore, reduced sensitivity to thermal stimuli
indicates a reduced number of C-fibers after transection (see also
[20]). Our study also showed that TRPV1 expression shifted to
myelinated fibers after transection. In the sham-operated group,
TRPV1 was mostly expressed in small size C-fibers. However, in
the IAN-transected groups, TRPV1 was mostly expressed in
medium sized-neurons, in both NP and non NP groups. These
results fit well with previous studies which also showed TRPV1
expression shifting to myelinated neurons in the dorsal root
ganglion of rats with chronic inflammatory conditions induced by
Freund’s complete adjuvant [55,56]. Similar shifting has also been
reported in animal models for diabetic neuropathy and bone
cancer pain [57,58,59]. Although medium sized myelinated fibers
are traditionally not involved in pain detection, these fibers have
been reported to be involved in NP after nerve injury
[20,21,39,48,50,60]. Background activity, mechanically evoked
responses and discharge of Ad-fibers increased significantly in
IAN-transected rats compared with naı¨ve rats [20]. In other
studies, it has been reported that after nerve injury, A-fibers were
able to produce substance P and calcitonin gene-related peptide
(CGRP), usually released from C-fibers [61,62,63]. Central
sprouting of myelinated fibers has also been postulated to be an
underlying cause of NP after nerve injury [48,60,64,65]. There-
fore, it is certainly plausible that entry of QX-314 into myelinated
fibers via TRPV1 activated by capsaicin, may block abnormal
activity of those fibers under neuropathic conditions and that these
fibers have a role in NP related behavior. A detailed knowledge of
expression profiles together with profound understanding of
myelinated and non-myelinated neurons contributing to neurop-
athy, will lead to successful development of strategies in
attenuating neuropathic pain.
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